Overall Survival and Progression Free Survival of Patients with Large Cell Neuroendocrine Lung Cancer and Combined Large Cell Neuroendocrine Lung Cancer Treated in Clinical Stage I-IV


Introduction: Large cell neuroendocrine cancer (LCNEC) is characterized rare incidence and poor prognosis.

Aim(s): The aim of the study was to estimate the survival of large cell neuroendocrine lung cancer and combined LCNEC and identify prognostic factors of OS and PFS.

Materials and methods: All patients in stage I-IV LCNEC and combined LCNEC recorded between 2002-2018 were included. OS and PFS were estimated by Kaplan Meier method. Uni- and multivariable analysis was estimated by Cox-regression model. A p value <0.05 was considered to be significant.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Łowczak A, Kolasińska-Ćwikła A, Osowiecka K, Ćwikła J, Rzepko R,

Keywords: Large cell neuroendocrine cancer, Overall survival, Progression-free survival,

To read the full abstract, please log into your ENETS Member account.